Autoimmune & Rheumatology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Multi-Center PAMPA Study

This trial is testing a biologic drug called guselkumab in people with psoriasis who are at high risk of developing psoriatic arthritis. The goal is to see if the drug can prevent or reduce joint inflammation and damage before arthritis fully develops. This study is currently recruiting participants in North America and will provide important information after two years of treatment about whether early intervention can protect joints in psoriasis patients.

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

The SAVE-Care trial is studying empagliflozin, a pill normally used for diabetes, to see if it can lower uric acid levels and inflammation in adults with gout. Lower uric acid may reduce painful gout flares and improve symptoms. This Phase 4 study is enrolling 60 patients and could lead to new treatment options for people living with gout and high uric acid.

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

This Phase 3 study is testing sonelokimab, an injectable treatment, in adults with active psoriatic arthritis who have not previously used biologic drugs. If effective, sonelokimab could offer a new way to improve symptoms and quality of life for people with this chronic arthritis. The trial is active across many locations worldwide and aims to provide data that will guide future treatment choices.

Metformin for Fibromyalgia Symptoms (INFORM Trial)

This study is exploring whether low-dose metformin, a drug commonly used for diabetes, can help reduce pain and fatigue in people with fibromyalgia. Fibromyalgia symptoms can be hard to manage, and this Phase 2 trial is recruiting participants in the United States to assess if metformin could be a helpful new option. The trial plans to enroll 72 people to better understand its effects on this condition.

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

This early phase trial is testing a new cell therapy called rapcabtagene autoleucel for adults with rheumatoid arthritis and severe Sjogren's disease who have not responded well to other treatments. The study aims to evaluate safety and how the therapy works in the body, with the hope it could offer a new option for difficult-to-treat cases. Multiple sites in several countries are currently recruiting participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.